Drug Profile
Atorvastatin/metformin controlled release - HK inno.N
Alternative Names: Aomet SR Tab.; Atomet SR Tab.; CJ-30056; Metformin/atorvastatin controlled releaseLatest Information Update: 30 Jun 2020
Price :
$50
*
At a glance
- Originator CJ HealthCare
- Developer HK inno.N
- Class Antihyperglycaemics; Antihyperlipidaemics; Biguanides; Fatty acids; Heptanoic acids; Pyrroles; Small molecules
- Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Hyperlipidaemia; Type 2 diabetes mellitus
Highest Development Phases
- Marketed Hyperlipidaemia; Type 2 diabetes mellitus
Most Recent Events
- 18 Jun 2020 CJ HealthCare is now called HK inno.N
- 12 Nov 2018 Chemical structure information added
- 25 Oct 2018 Launched for Hyperlipidaemia in South Korea (PO), prior October 2018 (CJ Healthcare pipeline, October 2018)